ECTRIMS 2021
Read the full Report (pdf)
European Committee for Treatment and Research in Multiple Sclerosis 13–15 October 2021
Featured articles
Preliminary data shows positive results of ATA188 for progressive MS
ECTRIMS 2021 Highlights Podcast
CONTENTS
Online First
COVID-19
MS patients at risk of hampered immune response after vaccination
Immunotherapy in MS does not influence COVID-19 severity and mortality
Anti-CD20 antibodies associated with worse COVID-19 outcomes
ECTRIMS-EAN consensus on vaccination in MS patients
Experimental Treatments
The role of astrocyte phenotypes in acute MS lesions
Promising results of intrathecal MSC-NTF cells in progressive MS
Preliminary data shows positive results of ATA188 for progressive MS
Evobrutinib reduces relapses and MRI lesion activity
Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial
Elezanumab did not outperform placebo in progressive and relapsing MS
Ibudilast reduced retinal atrophy in primary progressive MS
Treatment Trials and Strategies
ECTRIMS/EAN Clinical Guidelines on MS treatment: an update
Rituximab most effective initial MS therapy in Swedish real-world study
Ublituximab meets primary endpoint for relapsing MS
Dynamic scoring system aids decision to switch MS therapies early
Long-term suppression of MRI disease activity with ocrelizumab
Stopping DMT: when or if at all?
Biomarkers
Early predictors of disability progression in paediatric-onset MS
High-sensitive biomarker detection in MS via novel ELISA assay
Cortical lesions predict cognitive impairment 20 years after MS diagnosis
Applicability of sNfL measurement in clinical practice
MRI more sensitive for disease activity than relapses in SPMS
Imaging
Changes in GABA-receptor binding among cognitively impaired MS patients
T2 lesions independently predict early conversion to SPMS
Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Eculizumab, satralizumab, or inebilizumab for NMOSD?
Long-term efficacy of satralizumab for NMOSD
Long-term efficacy data: inebilizumab for NMOSD
Progressive MS
Charcot Award 2021: Progressive MS, a personal perspective
Top score poster: Meta-analysis on the effect of DMTs
Cortical lesions predict disease progression and disability accumulation
Ocrelizumab shows long-term benefits in primary progressive MS
Other
WNT9B-gene variant associated with doubled relapse risk in MS
